Prostate cancer (PCa) is no exception: well-differentiated, low-grade tumors (i.e., Gleason 6-7) contain glandular structures with tumor cells expressing differentiation markers such as androgen receptor (AR) and prostate-specific antigen (PSA). This evidence concerns the gene AR and neoplasm.